Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis

This analysis reviews data of patients who underwent a second autologous stem cell transplant for myeloma, including median progression-free survival, median interval between each patient’s two transplants, median age of the cohort, and median dose of stem cells infused, as well as the overall response rate on day +100.